Withaferin A is a potent inhibitor of angiogenesis

Royce Mohan, Hans Hammers, Paola Bargagna-Mohan, Xiaoguo Zhan, Christopher Herbstritt, Antonio Ruiz, Li Zhang, Art Hanson, Barry Conner, John Rougas, Victor Pribluda

Research output: Contribution to journalArticle

240 Citations (Scopus)

Abstract

The medicinal plant Withania somnifera is widely researched for its anti-inflammatory, cardioactive and central nervous system effects. In Ayurveda, the major Traditional Indian medicine system, extracts from W. somnifera are distinctively employed for the treatment of arthritis and menstrual disorders. Because these conditions involve angiogenic processes we hypothesized that the W. somnifera extracts might contain angiogenesis inhibitors. We employed an endothelial cell-sprouting assay to monitor the purification of substances from W. somnifera root extracts and isolated as the active principle the previously known natural product withaferin A. We show that withaferin A inhibits human umbilical vein endothelial cell (HUVEC) sprouting in three-dimensional collagen-I matrix at doses which are relevant to NF-kappa B-inhibitory activity. Withaferin A inhibits cell proliferation in HUVECs (IC 50=12 nM) at doses that are significantly lower than those required for tumor cell lines through a process associated with inhibition of cyclin D1 expression. We propose that the inhibition of NF-kappa B by withaferin A in HUVECs occurs by interference with the ubiquitin-mediated proteasome pathway as suggested by the increased levels of poly-ubiquitinated proteins. Finally, withaferin A is shown to exert potent anti-angiogenic activity in vivo at doses that are 500-fold lower than those previously reported to exert anti-tumor activity in vivo. In conclusion, our findings identify a novel mode of action of withaferin A, which highlights the potential use of this natural product for cancer treatment or prevention.

Original languageEnglish (US)
Pages (from-to)115-122
Number of pages8
JournalAngiogenesis
Volume7
Issue number2
DOIs
StatePublished - Nov 24 2004

Fingerprint

Angiogenesis Inhibitors
Endothelial cells
Withania
Tumors
Oncology
Cell proliferation
Neurology
Collagen
Medicine
Purification
Assays
NF-kappa B
Cells
Biological Products
Proteins
Ubiquitinated Proteins
Cyclin D1
Human Umbilical Vein Endothelial Cells
Traditional Medicine
Proteasome Endopeptidase Complex

Keywords

  • angiogenesis inhibitor
  • endothelial cell
  • natural product
  • NF-kappa B
  • withaferin A

ASJC Scopus subject areas

  • Cancer Research
  • Pathology and Forensic Medicine
  • Clinical Biochemistry
  • Polymers and Plastics

Cite this

Mohan, R., Hammers, H., Bargagna-Mohan, P., Zhan, X., Herbstritt, C., Ruiz, A., ... Pribluda, V. (2004). Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis, 7(2), 115-122. https://doi.org/10.1007/s10456-004-1026-3

Withaferin A is a potent inhibitor of angiogenesis. / Mohan, Royce; Hammers, Hans; Bargagna-Mohan, Paola; Zhan, Xiaoguo; Herbstritt, Christopher; Ruiz, Antonio; Zhang, Li; Hanson, Art; Conner, Barry; Rougas, John; Pribluda, Victor.

In: Angiogenesis, Vol. 7, No. 2, 24.11.2004, p. 115-122.

Research output: Contribution to journalArticle

Mohan, R, Hammers, H, Bargagna-Mohan, P, Zhan, X, Herbstritt, C, Ruiz, A, Zhang, L, Hanson, A, Conner, B, Rougas, J & Pribluda, V 2004, 'Withaferin A is a potent inhibitor of angiogenesis', Angiogenesis, vol. 7, no. 2, pp. 115-122. https://doi.org/10.1007/s10456-004-1026-3
Mohan R, Hammers H, Bargagna-Mohan P, Zhan X, Herbstritt C, Ruiz A et al. Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis. 2004 Nov 24;7(2):115-122. https://doi.org/10.1007/s10456-004-1026-3
Mohan, Royce ; Hammers, Hans ; Bargagna-Mohan, Paola ; Zhan, Xiaoguo ; Herbstritt, Christopher ; Ruiz, Antonio ; Zhang, Li ; Hanson, Art ; Conner, Barry ; Rougas, John ; Pribluda, Victor. / Withaferin A is a potent inhibitor of angiogenesis. In: Angiogenesis. 2004 ; Vol. 7, No. 2. pp. 115-122.
@article{120e2ff98bbc4e69ae406de4d3aa2519,
title = "Withaferin A is a potent inhibitor of angiogenesis",
abstract = "The medicinal plant Withania somnifera is widely researched for its anti-inflammatory, cardioactive and central nervous system effects. In Ayurveda, the major Traditional Indian medicine system, extracts from W. somnifera are distinctively employed for the treatment of arthritis and menstrual disorders. Because these conditions involve angiogenic processes we hypothesized that the W. somnifera extracts might contain angiogenesis inhibitors. We employed an endothelial cell-sprouting assay to monitor the purification of substances from W. somnifera root extracts and isolated as the active principle the previously known natural product withaferin A. We show that withaferin A inhibits human umbilical vein endothelial cell (HUVEC) sprouting in three-dimensional collagen-I matrix at doses which are relevant to NF-kappa B-inhibitory activity. Withaferin A inhibits cell proliferation in HUVECs (IC 50=12 nM) at doses that are significantly lower than those required for tumor cell lines through a process associated with inhibition of cyclin D1 expression. We propose that the inhibition of NF-kappa B by withaferin A in HUVECs occurs by interference with the ubiquitin-mediated proteasome pathway as suggested by the increased levels of poly-ubiquitinated proteins. Finally, withaferin A is shown to exert potent anti-angiogenic activity in vivo at doses that are 500-fold lower than those previously reported to exert anti-tumor activity in vivo. In conclusion, our findings identify a novel mode of action of withaferin A, which highlights the potential use of this natural product for cancer treatment or prevention.",
keywords = "angiogenesis inhibitor, endothelial cell, natural product, NF-kappa B, withaferin A",
author = "Royce Mohan and Hans Hammers and Paola Bargagna-Mohan and Xiaoguo Zhan and Christopher Herbstritt and Antonio Ruiz and Li Zhang and Art Hanson and Barry Conner and John Rougas and Victor Pribluda",
year = "2004",
month = "11",
day = "24",
doi = "10.1007/s10456-004-1026-3",
language = "English (US)",
volume = "7",
pages = "115--122",
journal = "Angiogenesis",
issn = "0969-6970",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Withaferin A is a potent inhibitor of angiogenesis

AU - Mohan, Royce

AU - Hammers, Hans

AU - Bargagna-Mohan, Paola

AU - Zhan, Xiaoguo

AU - Herbstritt, Christopher

AU - Ruiz, Antonio

AU - Zhang, Li

AU - Hanson, Art

AU - Conner, Barry

AU - Rougas, John

AU - Pribluda, Victor

PY - 2004/11/24

Y1 - 2004/11/24

N2 - The medicinal plant Withania somnifera is widely researched for its anti-inflammatory, cardioactive and central nervous system effects. In Ayurveda, the major Traditional Indian medicine system, extracts from W. somnifera are distinctively employed for the treatment of arthritis and menstrual disorders. Because these conditions involve angiogenic processes we hypothesized that the W. somnifera extracts might contain angiogenesis inhibitors. We employed an endothelial cell-sprouting assay to monitor the purification of substances from W. somnifera root extracts and isolated as the active principle the previously known natural product withaferin A. We show that withaferin A inhibits human umbilical vein endothelial cell (HUVEC) sprouting in three-dimensional collagen-I matrix at doses which are relevant to NF-kappa B-inhibitory activity. Withaferin A inhibits cell proliferation in HUVECs (IC 50=12 nM) at doses that are significantly lower than those required for tumor cell lines through a process associated with inhibition of cyclin D1 expression. We propose that the inhibition of NF-kappa B by withaferin A in HUVECs occurs by interference with the ubiquitin-mediated proteasome pathway as suggested by the increased levels of poly-ubiquitinated proteins. Finally, withaferin A is shown to exert potent anti-angiogenic activity in vivo at doses that are 500-fold lower than those previously reported to exert anti-tumor activity in vivo. In conclusion, our findings identify a novel mode of action of withaferin A, which highlights the potential use of this natural product for cancer treatment or prevention.

AB - The medicinal plant Withania somnifera is widely researched for its anti-inflammatory, cardioactive and central nervous system effects. In Ayurveda, the major Traditional Indian medicine system, extracts from W. somnifera are distinctively employed for the treatment of arthritis and menstrual disorders. Because these conditions involve angiogenic processes we hypothesized that the W. somnifera extracts might contain angiogenesis inhibitors. We employed an endothelial cell-sprouting assay to monitor the purification of substances from W. somnifera root extracts and isolated as the active principle the previously known natural product withaferin A. We show that withaferin A inhibits human umbilical vein endothelial cell (HUVEC) sprouting in three-dimensional collagen-I matrix at doses which are relevant to NF-kappa B-inhibitory activity. Withaferin A inhibits cell proliferation in HUVECs (IC 50=12 nM) at doses that are significantly lower than those required for tumor cell lines through a process associated with inhibition of cyclin D1 expression. We propose that the inhibition of NF-kappa B by withaferin A in HUVECs occurs by interference with the ubiquitin-mediated proteasome pathway as suggested by the increased levels of poly-ubiquitinated proteins. Finally, withaferin A is shown to exert potent anti-angiogenic activity in vivo at doses that are 500-fold lower than those previously reported to exert anti-tumor activity in vivo. In conclusion, our findings identify a novel mode of action of withaferin A, which highlights the potential use of this natural product for cancer treatment or prevention.

KW - angiogenesis inhibitor

KW - endothelial cell

KW - natural product

KW - NF-kappa B

KW - withaferin A

UR - http://www.scopus.com/inward/record.url?scp=20844449388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20844449388&partnerID=8YFLogxK

U2 - 10.1007/s10456-004-1026-3

DO - 10.1007/s10456-004-1026-3

M3 - Article

C2 - 15516832

AN - SCOPUS:20844449388

VL - 7

SP - 115

EP - 122

JO - Angiogenesis

JF - Angiogenesis

SN - 0969-6970

IS - 2

ER -